Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by tylerreddickon May 14, 2024 10:07pm
116 Views
Post# 36040183

RE:RE:RE:RE:RE:RE:New investor

RE:RE:RE:RE:RE:RE:New investor
biorun wrote: they keep saying in their updates etc that Abbvie is still quite engaged and they are progressing towards commercialization.

based upon that, we have no reason to believe that isn't the case. 

i keep saying that product launch updates at allergan is typically every 2 years. that would make it january 2023 when they last updated their skin lightening line up, 

the current stock price doesn't believe that will happen. I am betting it will unless something tells me otherwise.


You obviously haven't been investing for long, as companies always blow sunshine up your posterior until they are forced to come clean.

I am hoping that SBM will pull the rabbit out of their hat, but their failure to find a backer for GlycoProtmim on their own isn't encouraging. 
<< Previous
Bullboard Posts
Next >>